AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$TXG

Taich Adam sold $1.1M of TXG

Taich Adam (Chief Financial Officer) sold 17,166 shares of 10x Genomics, Inc. (TXG) at $63.02 ($1.08M total) on 2026-08-24.

Original reporting
SEC EDGAR · Taich Adam
Published Aug 26, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TXG
Bearish
medium confidence
Mentioned
$TXG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TXGBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, useful for short-term trading decisions.

02

Market read

Insider sale adds a modest bearish nuance to 10x Genomics' stock outlook.

03

What to watch

The CFO's holdings remain sizable; no immediate dilution risk.

Relevance 6/10Novelty 5/10Timing: filed on 2026-08-26

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$TXGBearishMedium confidence
Context

CFO Taich Adam sold 17,166 shares of 10x Genomics for $1.08M, reducing his stake to 362,732 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

A $1M sale by a senior officer is material for a mid-cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May prompt scrutiny of insider activity in biotech sector.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    10x Genomics, Inc.

    Biotech firm developing genomic analysis platforms.

  • Person
    Taich Adam

    Chief Financial Officer of 10x Genomics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TXG insider trading history →

Related articles

OCT 12
$TXGMed

Why is 10X Genomics stock down 10% today?

10X Genomics (TXG) shares fell 10.3% to $72.33 amid volatility and valuation reassessment. Canaccord Genuity raised its price target to $100, but analysts' consensus remains 'Hold' with a $58.60 average target. Insider selling and declining revenue add pressure. The stock has been volatile, dropping 13.4% and 6.2% on Oct. 6 and 8, respectively.

investing.com2 min
OCT 9
$TXGHigh

Why Are 10x Genomics (TXG) Shares Soaring Today

10x Genomics (TXG) shares rose 6.1% after Bank of America raised its price target to $80 from $50, citing improved sentiment and consumables revenue growth. The firm maintained a Neutral rating, noting hardware revenue volatility and operating losses. TXG is up 391% year-to-date but trades 16.5% below its 52-week high.

financialcontent.com1 min
SEP 28
$TXGMed

10x Genomics (TXG) Stock Is Up, What You Need To Know

10x Genomics (TXG) shares rose 3.2% to $88.45 after Argus initiated coverage with a Buy rating. The stock has gained 432% year-to-date, reaching a 52-week high. Argus's rating suggests positive returns or outperformance. The company's shares are highly volatile, with significant moves over the past year.

financialcontent.com1 min
SEP 24
$TXGMed

TXG Stock Jumps As AI Partnership And Legal Win Shift Outlook

10x Genomics Inc. (TXG) stock rose 13.01% on September 24, 2026, driven by an AI partnership with Lunit and a patent win against Qiagen. The company's stock has surged from $59.98 to $84.11 over recent weeks. TXG reported $642.8M in revenue with strong gross margins but negative operating margins. Analysts have mixed views, with price targets ranging from $60s to $70.

timothysykes.com3 min